Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University, discusses key findings and patient attitudes toward precision approaches to quitting smoking.
Patients are generally enthusiastic about precision approaches to quitting smoking in pilot studies, and randomized controlled trials (RCTs) are ongoing, said Hilary Tindle, MD, MPH, associate professor of medicine at Vanderbilt University.
Transcript
What were some of your findings from the pilot precision RCTs you participated in, and what were patient attitudes towards them?
We have conducted a couple of pilots and we're conducting a larger clinical trial now that is not finished, it's still ongoing. But in our pilot work, one was in the hospital clinic setting and another was in the community setting through the Southern Community Cohort Study, which is a longitudinal cohort of 12 states in the South that overlaps with Tobacco Nation.
We uniformly found that people are enthusiastic about precision approaches to quitting smoking, and that's across all groups. There were some groups, of course, who were a little less enthusiastic, but that's what you're going to find with any new therapy. And all that it means is that people need to see good evidence, they need to know that what they're accepting is high-value care. But in general, most people, if they're asked, would you take a blood test if your doctor could order it, and it could help choose the best medicine for you to quit smoking? Most people endorse that with a yes.
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
Bimekizumab Poised to Tackle Unmet HS Treatment Needs
October 18th 2024Hidradenitis suppurativa (HS) is an inflammatory, chronic disease with very high symptom and physical burdens, and it can get progressively worse over time if it's inadequately treated, explained Amit Garg, MD, founding chair, Department of Dermatology, Northwell Health.
Read More
Expanding Access to NSCLC Innovations: Challenges and Opportunities
October 18th 2024The current research focus for Umit Tapan, MD, Boston Medical Center, is reducing disparities in lung cancer care and improving treatment access, in particular for immunotherapy and targeted treatments.
Read More